Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cyclarity Therapeutics Inc. focuses its patent prosecution efforts within the Chemistry & Materials technology area. The company currently has 1 pending office action that requires a formal response. This specific workload is handled by 1 distinct examiner, which indicates a concentrated prosecution environment for the company's current filings. Furthermore, the active matter is situated within 1 distinct art unit, ensuring that the technical review is conducted by a specialized group at the patent office.
The busiest examiner for this portfolio is KOLB, KATARZYNA I, who is responsible for 1 busiest examiner pending office action. Since the total number of pending office actions is 1, this examiner is currently managing the entirety of the company's active prosecution. Practitioners should monitor the specific tendencies and past decisions of KOLB, KATARZYNA I to anticipate potential challenges in the Chemistry & Materials sector. The alignment of 1 distinct examiner with 1 distinct art unit suggests that the company can maintain a singular focus during the response phase without the need to coordinate across different technical departments or examiner styles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOLB, KATARZYNA I | 1 | 45.3% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004579 | CYCLODEXTRIN DIMERS AND USES THEREOF | KOLB, KATARZYNA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004579 | CYCLODEXTRIN DIMERS AND USES THEREOF | KOLB, KATARZYNA I | — |
| Art Unit | Apps |
|---|---|
| 1767 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18004579 | CYCLODEXTRIN DIMERS AND USES THEREOF | KOLB, KATARZYNA I | 1767 | §102§103§112Other | Final Rejection | — | Pending | Oct 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCyclarity Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Katarzyna I Kolb has the most, with 1 of Cyclarity Therapeutics Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.